CVS Health (CVS) earnings Q1 2026
A screen displays the logo and trading information for CVS at the New York Stock Exchange, March 24,…
Weight-Loss Drugs Like Ozempic May Come With an Unexpected Cost
Glucagon-like peptide-1 (GLP-1) medications are drugs used to treat type 2 diabetes and support weight loss. They mimic…
FDA withdrew studies finding Covid, shingles vaccines were safe
The FDA blocked the publication of several studies supporting the safety of vaccines against Covid and shingles in…
UnitedHealth, Cigna, Humana earnings show insurers are recovering
Piotr Swat | SOPA Images | Lightrocket | Getty Images Major health insurers appear to be off to…
Pfizer (PFE) earnings Q1 2026
Exterior view of the Pfizer headquarters building on January 29, 2023 in New York City. View Press |…
Popular Weight-Loss Drugs Found To Cut Heart Attack and Stroke Risk
GLP-1 receptor agonists are showing evidence of sustained cardiovascular effects beyond their established metabolic benefits. Long-term trial data…
FDA proposes excluding Novo, Lilly GLP-1s from compounding list
The headquarters of the U.S. Food and Drug Administration in Silver Spring, Maryland, Nov. 4, 2009. Jason Reed…
Eli Lilly (LLY) earnings Q1 2026
Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates and hiked its full-year sales…
FDA testing speedier drug development with real-time clinical trials
WASHINGTON — The Food and Drug Administration on Tuesday announced efforts to make clinical trials more efficient, starting…
Reality of Trump’s drug pricing to set in over next 18 months
Novartis‘ CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult…
Erasca touts strong early results in pancreatic and lung cancer therapy trial
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
Ajax’s lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with…